Radiation as an Immune Modulator

Seminars in Radiation Oncology

Volumn 23, Issue 4, 2013, Pages 273-280

  Burnette, Byron ^a   Weichselbaum, Ralph R ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOTHELIAL LEUKOCYTE ADHESION MOLECULE 1; GAMMA INTERFERON; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 1; INTERLEUKIN 10; INTERLEUKIN 6; MACROPHAGE DERIVED CHEMOKINE; STAT1 PROTEIN; STROMAL CELL DERIVED FACTOR 1; TRANSCRIPTION FACTOR FOXP3; VASCULAR CELL ADHESION MOLECULE 1; VASCULOTROPIN;

ADAPTIVE IMMUNITY; ANTIGEN PRESENTATION; ANTIGENICITY; APOPTOSIS; ARTICLE; BONE MARROW CELL; CANCER RADIOTHERAPY; CELL DEATH; CELL FUNCTION; CELL MATURATION; CELL PROLIFERATION; CELL STRESS; CELL SURFACE; CYTOKINE PRODUCTION; CYTOKINE RELEASE; CYTOTOXICITY; DENDRITIC CELL; HUMAN; HYDROLYSIS; IMMUNOGENICITY; IMMUNOMODULATION; IMMUNOSTIMULATION; IMMUNOTHERAPY; INFLAMMATION; INNATE IMMUNITY; IONIZING RADIATION; LEUKOCYTE; LYMPHOCYTIC INFILTRATION; NONHUMAN; PLEIOTROPY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RADIATION RESPONSE; RADIOTHERAPY; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION; TUMOR CELL; TUMOR MICROENVIRONMENT; UPREGULATION;

CELL DEATH; CYTOKINES; DNA BREAKS, DOUBLE-STRANDED; HUMANS; IMMUNITY, INNATE; INFLAMMATION; NEOPLASMS; RADIATION TOLERANCE; TUMOR MICROENVIRONMENT;

EID: 84883546634     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.05.009     Document Type: Article

References (93)

1. Philip M., Rowley D.A., Schreiber H. Inflammation as a tumor promoter in cancer induction. Semin Cancer Biol 2004, 14:433-439.
2. Li Q., Withoff S., Verma I.M. Inflammation-associated cancer: NF-kappaB is the lynchpin. Trends Immunol 2005, 26:318-325.
3. Lin W.-W., Karin M. A cytokine-mediated link between innate immunity, inflammation, and cancer. J Clin Invest 2007, 117:1175-1183.
4. de Visser K.E., Eichten A., Coussens L.M. Paradoxical roles of the immune system during cancer development. Nat Rev Cancer 2006, 6:24-37.
5. Schaue D., McBride W.H. Links between innate immunity and normal tissue radiobiology. Radiat Res 2010, 173:406-417.
6. Brach M.A., Hass R., Sherman M.L., et al. Ionizing radiation induces expression and binding activity of the nuclear factor kappa B. J Clin Invest 1991, 88:691-695.
7. Mohan N., Meltz M.L. Induction of nuclear factor kappa B after low-dose ionizing radiation involves a reactive oxygen intermediate signaling pathway. Radiat Res 1994, 140:97-104.
8. Liu Z.G., Baskaran R., Lea-Chou E.T., et al. Three distinct signalling responses by murine fibroblasts to genotoxic stress. Nature 1996, 384:273-276.
9. Li N., Karin M. Ionizing radiation and short wavelength UV activate NF-kappaB through two distinct mechanisms. Proc Natl Acad Sci U S A 1998, 95:13012-13017.
10. Criswell T., Leskov K., Miyamoto S., et al. Transcription factors activated in mammalian cells after clinically relevant doses of ionizing radiation. Oncogene 2003, 22:5813-5827.
11. Lavin M.F. Ataxia-telangiectasia: From a rare disorder to a paradigm for cell signalling and cancer. Nat Rev Mol Cell Biol 2008, 9:759-769.
12. Hallahan D.E., Spriggs D.R., Beckett M.A., et al. Increased tumor necrosis factor alpha mRNA after cellular exposure to ionizing radiation. Proc Natl Acad Sci U S A 1989, 86:10104-10107.
13. O'Brien-Ladner A., Nelson M.E., Kimler B.F., et al. Release of interleukin-1 by human alveolar macrophages after in vitro irradiation. Radiat Res 1993, 136:37-41.
14. Hong J.H., Chiang C.S., Tsao C.Y., et al. Rapid induction of cytokine gene expression in the lung after single and fractionated doses of radiation. Int J Radiat Biol 1999, 75:1421-1427.
15. Iademarco M.F., McQuillan J.J., Rosen G.D., et al. Characterization of the promoter for vascular cell adhesion molecule-1 (VCAM-1). J Biol Chem 1992, 267:16323-16329.
16. Schindler U., Baichwal V.R. Three NF-kappa B binding sites in the human E-selectin gene required for maximal tumor necrosis factor alpha-induced expression. Mol Cell Biol 1994, 14:5820-5831.
17. van de Stolpe A., Caldenhoven E., Stade B.G., et al. 12-O-tetradecanoylphorbol-13-acetate- and tumor necrosis factor alpha-mediated induction of intercellular adhesion molecule-1 is inhibited by dexamethasone. Functional analysis of the human intercellular adhesion molecular-1 promoter. J Biol Chem 1994, 269:6185-6192.
18. Hallahan D., Kuchibhotla J., Wyble C. Cell adhesion molecules mediate radiation-induced leukocyte adhesion to the vascular endothelium. Cancer Res 1996, 56:5150-5155.
19. Handschel J., Prott F.J., Sunderkötter C., et al. Irradiation induces increase of adhesion molecules and accumulation of beta2-integrin-expressing cells in humans. Int J Radiat Oncol Biol Phys 1999, 45:475-481.
20. Shiao S.L., Coussens L.M. The tumor-immune microenvironment and response to radiation therapy. J Mammary Gland Biol Neoplasia 2010, 15:411-421.
21. Burnette B.C., Liang H., Lee Y., et al. The efficacy of radiotherapy relies upon induction of type i interferon-dependent innate and adaptive immunity. Cancer Res 2011, 71:2488-2496.
22. + T cells via dendritic cell activation. J Immunol 2012, 189:558-566.
23. Garcia-Barros M. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science 2003, 300:1155-1159.
24. + T cells: Changing strategies for cancer treatment. Blood 2009, 114:589-595.
25. Lugade A.A., Moran J.P., Gerber S.A., et al. Local radiation therapy of B16 melanoma tumors increases the generation of tumor antigen-specific effector cells that traffic to the tumor. J Immunol 2005, 174:7516-7523.
26. Gough M.J., Crittenden M.R., Sarff M., et al. Adjuvant therapy with agonistic antibodies to CD134 (OX40) increases local control after surgical or radiation therapy of cancer in mice. J Immunother 2010, 33:798-809.
27. Lugade A.A., Sorensen E.W., Gerber S.A., et al. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol 2008, 180:3132-3139.
28. Caldenhoven E., Coffer P., Yuan J., et al. Stimulation of the human intercellular adhesion molecule-1 promoter by interleukin-6 and interferon-gamma involves binding of distinct factors to a palindromic response element. J Biol Chem 1994, 269:21146-21154.
29. + T cells. Mol Ther 2010, 18:912-920.
30. Matsumura S., Wang B., Kawashima N., et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol 2008, 181:3099-3107.
31. Matsumura S., Demaria S. Up-regulation of the pro-inflammatory chemokine CXCL16 is a common response of tumor cells to ionizing radiation. Radiat Res 2010, 173:418-425.
32. Zong Z.-W., Cheng T-M, Su Y-P, et al. Recruitment of transplanted dermal multipotent stem cells to sites of injury in rats with combined radiation and wound injury by interaction of SDF-1 and CXCR4. Radiat Res 2008, 170:444-450.
33. Jäger D., Jäger E., Knuth A. Immune responses to tumour antigens: Implications for antigen specific immunotherapy of cancer. J Clin Pathol 2001, 54:669-674.
34. Boon T. Human tumor antigens recognized by T lymphocytes. J Exp Med 1996, 183:725-729.
35. Scanlan M.J., Gure A.O., Jungbluth A.A., et al. Cancer/testis antigens: An expanding family of targets for cancer immunotherapy. Immunol Rev 2002, 188:22-32.
36. Engelhard V.H., Bullock T.N.J., Colella T.A., et al. Antigens derived from melanocyte differentiation proteins: Self-tolerance, autoimmunity, and use for cancer immunotherapy. Immunol Rev 2002, 188:136-146.
37. Tabatabai G., Frank B., Möhle R., et al. Irradiation and hypoxia promote homing of haematopoietic progenitor cells towards gliomas by TGF-beta-dependent HIF-1alpha-mediated induction of CXCL12. Brain 2006, 129:2426-2435.
38. Santin A.D., Hermonat P.L., Ravaggi A., et al. Radiation-enhanced expression of E6/E7 transforming oncogenes of human papillomavirus-16 in human cervical carcinoma. Cancer 1998, 83:2346-2352.
39. Sharma A., Bode B., Wenger R.H., et al. γ-Radiation promotes immunological recognition of cancer cells through increased expression of cancer-testis antigens in vitro and in vivo. PLoS One 2011, 6:e28217.
40. Reits E.A., Hodge J.W., Herberts C.A., et al. Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy. J Exp Med 2006, 203:1259-1271.
41. Kozin S.V., Kamoun W.S., Huang Y., et al. Recruitment of myeloid but not endothelial precursor cells facilitates tumor regrowth after local irradiation. Cancer Res 2010, 70:5679-5685.
42. Chiang C-S, Fu SY, Wang SC, et al: Irradiation promotes an M2 macrophage phenotype in tumor hypoxia. Front Oncol 2:89, 2012. doi:10.3389/fonc.2012.00089/abstract.
43. Wan S., Pestka S., Jubin R.G., et al. Chemotherapeutics and radiation stimulate MHC class i expression through elevated interferon-beta signaling in breast cancer cells. PLoS One 2012, 7:e32542.
44. Johnson D.R., Pober J.S. HLA class I heavy-chain gene promoter elements mediating synergy between tumor necrosis factor and interferons. Mol Cell Biol 1994, 14:1322-1332.
45. Newcomb E.W., Demaria S., Lukyanov Y., et al. The combination of ionizing radiation and peripheral vaccination produces long-term survival of mice bearing established invasive GL261 gliomas. Radiat Res 2010, 173:4730-4737.
46. Gasser S., Orsulic S., Brown E.J., et al. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005, 436:1186-1190.
47. González S., López-Soto A., Suarez-Alvarez B., et al. NKG2D ligands: Key targets of the immune response. Trends Immunol 2008, 29:397-403.
48. + CTL function: Similarities and differences between NKG2D and CD28 costimulation. J Immunol 2005, 175:2825-2833.
49. Champsaur M., Lanier L.L. Effect of NKG2D ligand expression on host immune responses. Immunol Rev 2010, 235:267-285.
50. Nausch N., Cerwenka A. NKG2D ligands in tumor immunity. Oncogene 2008, 27:5944-5958.
51. Drake C.G., Jaffee E., Pardoll D.M. Mechanisms of immune evasion by tumors. Adv Immunol 2006, 90:51-81.
52. Mantovani A., Romero P., Palucka A.K., et al. Tumour immunity: Effector response to tumour and role of the microenvironment. Lancet 2008, 371:771-783.
53. Marigo I., Dolcetti L., Serafini P., et al. Tumor-induced tolerance and immune suppression by myeloid derived suppressor cells. Immunol Rev 2008, 222:162-179.
54. Grohmann U., Bronte V. Control of immune response by amino acid metabolism. Immunol Rev 2010, 236:243-264.
55. Facciabene A., Motz G.T., Coukos G. T-regulatory cells: Key players in tumor immune escape and angiogenesis. Cancer Res 2012, 72:2162-2171.
56. Bunt S.K., Yang L., Sinha P., et al. Reduced inflammation in the tumor microenvironment delays the accumulation of myeloid-derived suppressor cells and limits tumor progression. Cancer Res 2007, 67:10019-10026.
57. Meng Y., Beckett M.A., Liang H., et al. Blockade of tumor necrosis factor signaling in tumor-associated macrophages as a radiosensitizing strategy. Cancer Res 2010, 70:1534-1543.
58. Ahn G.-O., Tseng D., Liao C-H, et al. Inhibition of Mac-1 (CD11b/CD18) enhances tumor response to radiation by reducing myeloid cell recruitment. Proc Natl Acad Sci U S A 2010, 107:8363-8368.
59. Ostrand-Rosenberg S. Myeloid-derived suppressor cells: More mechanisms for inhibiting antitumor immunity. Cancer Immunol Immunother 2010, 59:1593-1600.
60. Ostrand-Rosenberg S., Sinha P., Beury D.W., et al. Cross-talk between myeloid-derived suppressor cells (MDSC), macrophages, and dendritic cells enhances tumor-induced immune suppression. Semin Cancer Biol 2012, 22:275-281.
61. Kusmartsev S., Gabrilovich D.I. STAT1 signaling regulates tumor-associated macrophage-mediated T cell deletion. J Immunol 2005, 174:4880-4891.
62. + T cells in mice. Radiat Res 2010, 173:148-157.
63. Kachikwu E.L., Iwamoto K.S., Liao Y-P, et al. Radiation enhances regulatory T cell representation. Int J Radiat Oncol Biol Phys 2011, 81:1128-1135.
64. Zitvogel L., Kepp O., Kroemer G. Decoding cell death signals in inflammation and immunity. Cell 2010, 140:798-804.
65. Kuraishy A., Karin M., Grivennikov S.I. Tumor promotion via injury- and death-induced inflammation. Immunity 2011, 35:467-477.
66. Rupnow B.A., Knox S.J. The role of radiation-induced apoptosis as a determinant of tumor responses to radiation therapy. Apoptosis 1999, 4:115-143.
67. Eriksson D., Stigbrand T. Radiation-induced cell death mechanisms. Tumor Biol 2010, 31:363-372.
68. Formenti SC, Pellicciotti I, Demaria S, et al: The convergence of radiation and immunogenic cell death signaling pathways. Front Onc 2:1-13, 2012.
69. Savill J., Dransfield I., Gregory C., et al. A blast from the past: Clearance of apoptotic cells regulates immune responses. Nat Rev Immunol 2002, 2:965-975.
70. Voll R.E., Herrmann M., Roth E.A., et al. Immunosuppressive effects of apoptotic cells. Nature 1997, 390:350-351.
71. Apetoh L., Ghiringhelli F., Tesniere A., et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007, 13:1050-1059.
72. Lotze M.T., Tracey K.J. High-mobility group box 1 protein (HMGB1): Nuclear weapon in the immune arsenal. Nat Rev Immunol 2005, 5:331-342.
73. Bianchi M.E., Manfredi A.A. High-mobility group box 1 (HMGB1) protein at the crossroads between innate and adaptive immunity. Immunol Rev 2007, 220:35-46.
74. Obeid M., Tesniere A., Ghiringhelli F., et al. Calreticulin exposure dictates the immunogenicity of cancer cell death. Nat Med 2006, 13:54-61.
75. Obeid M., Panaretakis T., Joza N., et al. Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC light-induced apoptosis. Cell Death Differ 2007, 14:1848-1850.
76. Elliott M.R., Chekeni F.B., Trampont P.C., et al. Nucleotides released by apoptotic cells act as a find-me signal to promote phagocytic clearance. Nature 2009, 461:282-286.
77. Steinman R.M., Hemmi H. Dendritic cells: Translating innate to adaptive immunity. Curr Top Microbiol Immunol 2006, 311:17-58.
78. Zhang B., Bowerman N.A., Salama J.K., et al. Induced sensitization of tumor stroma leads to eradication of established cancer by T cells. J Exp Med 2007, 204:49-55.
79. Ghiringhelli F., Apetoh L., Tesniere A., et al. Activation of the NLRP3 inflammasome in dendritic cells induces IL-1beta-dependent adaptive immunity against tumors. Nat Med 2009, 15:1170-1178.
80. Apte R.N., Voronov E. Is interleukin-1 a good or bad 'guy' in tumor immunobiology and immunotherapy?. Immunol Rev 2008, 222:222-241.
81. Burnette B., Fu Y.-X., Weichselbaum R.R. The confluence of radiotherapy and immunotherapy. Front Oncol 2012, 2:143.
82. Diamond M.S., Diamond M.S., Kinder M., Matsushita H., et al. Type I interferon is selectively required by dendritic cells for immune rejection of tumors. J Exp Med 2011, 208:1989-2003.
83. + dendritic cells. J Exp Med 2011, 208:2005-2016.
84. Younes E., Haas G.P., Dezso B., et al. Local tumor irradiation augments the response to IL-2 therapy in a murine renal adenocarcinoma. Cell Immunol 1995, 165:243-251.
85. Younes E., Haas G.P., Dezso B., et al. Radiation-induced effects on murine kidney tumor cells: Role in the interaction of local irradiation and immunotherapy. J Urol 1995, 153:2029-2033.
86. Everse L.A., Renes I.B., Jürgenliemk-Schulz I.M., et al. Local low-dose interleukin-2 induces systemic immunity when combined with radiotherapy of cancer. A pre-clinical study. Int J Cancer 1997, 72:1003-1007.
87. Seung S.K., Curti B.D., Crittenden M., et al. Phase 1 study of stereotactic body radiotherapy and interleukin-2-Tumor and immunological responses. Sci Transl Med 2012, 4:137ra74.
88. Demaria S., Kawashima N., Yang A.M., et al. Immune-mediated inhibition of metastases after treatment with local radiation and CTLA-4 blockade in a mouse model of breast cancer. Clin Cancer Res 2005, 11:728-734.
89. Dewan M.Z., Galloway A.E., Kawashima N., et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res 2009, 15:5379-5388.
90. Postow M.A., Callahan M.K., Barker C.A., et al. Immunologic correlates of the abscopal effect in a patient with melanoma. N Engl J Med 2012, 366:925-931.
91. Verbrugge I., Hagekyriakou J., Sharp L.L., et al. Radiotherapy increases the permissiveness of established mammary tumors to rejection by immunomodulatory antibodies. Cancer Res 2012, 72:3163-3174.
92. Peggs K.S., Quezada S.A., Korman A.J., et al. Principles and use of anti-CTLA4 antibody in human cancer immunotherapy. Curr Opin Immunol 2006, 18:206-213.
93. Topalian S.L., Drake C.G., Pardoll D.M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr Opin Immunol 2012, 24:207-212.